OBJECTIVE: Psychosocial interventions that are practical, transportable, and effective in promoting treatment adherence and efficacy are greatly needed in both research and clinical settings involving alcohol-dependence pharmacotherapy. In this article, we describe the development and preliminary evaluation of an integrative treatment blending motivational interviewing and compliance enhancement therapy (MI-CET) as a means of enhancing adherence and retention in an ongoing clinical trial. METHOD: Medication adherence, session attendance, and study completion rates were examined for 121 treatment-seeking, alcohol-dependent adults participating in a randomized clinical trial ofcitalopram (n = 81) versus placebo (n = 40). All participants received the manual-guided MI-CET intervention as an adjunct to pharmacotherapy. Preliminary adherence and retention data for this trial were compared with data from prior studies involving treatment for alcohol dependence with a selective serotonin reuptake inhibitor. RESULTS:High rates of medication adherence (79% of citalopram and 91% of placebo completers took > or = 80% of doses), session attendance (average of 90% for citalopram and 93% for placebo groups), and study completion (81% for citalopram and 88% for placebo groups) were obtained in the present study using MI-CET. These rates were at least comparable to or were, in some cases, 20%-30% higher than rates obtained in the comparison trials. CONCLUSIONS: These results suggest that MI-CET is feasible as a psychosocial adjunct to alcohol-dependence pharmacotherapy. Given its strengths as a clinical and research intervention (e.g., practicality, transportability), further evaluation of its efficacy is warranted.
RCT Entities:
OBJECTIVE:Psychosocial interventions that are practical, transportable, and effective in promoting treatment adherence and efficacy are greatly needed in both research and clinical settings involving alcohol-dependence pharmacotherapy. In this article, we describe the development and preliminary evaluation of an integrative treatment blending motivational interviewing and compliance enhancement therapy (MI-CET) as a means of enhancing adherence and retention in an ongoing clinical trial. METHOD: Medication adherence, session attendance, and study completion rates were examined for 121 treatment-seeking, alcohol-dependent adults participating in a randomized clinical trial of citalopram (n = 81) versus placebo (n = 40). All participants received the manual-guided MI-CET intervention as an adjunct to pharmacotherapy. Preliminary adherence and retention data for this trial were compared with data from prior studies involving treatment for alcohol dependence with a selective serotonin reuptake inhibitor. RESULTS: High rates of medication adherence (79% of citalopram and 91% of placebo completers took > or = 80% of doses), session attendance (average of 90% for citalopram and 93% for placebo groups), and study completion (81% for citalopram and 88% for placebo groups) were obtained in the present study using MI-CET. These rates were at least comparable to or were, in some cases, 20%-30% higher than rates obtained in the comparison trials. CONCLUSIONS: These results suggest that MI-CET is feasible as a psychosocial adjunct to alcohol-dependence pharmacotherapy. Given its strengths as a clinical and research intervention (e.g., practicality, transportability), further evaluation of its efficacy is warranted.
Authors: K M Carroll; C Nich; R L Sifry; K F Nuro; T L Frankforter; S A Ball; L Fenton; B J Rounsaville Journal: Drug Alcohol Depend Date: 2000-01-01 Impact factor: 4.492
Authors: H M Pettinati; J R Volpicelli; G Luck; H R Kranzler; M R Rukstalis; A Cnaan Journal: J Clin Psychopharmacol Date: 2001-04 Impact factor: 3.153
Authors: Stephanie S O'Malley; Bruce J Rounsaville; Conor Farren; Kee Namkoong; Ran Wu; Jane Robinson; Patrick G O'Connor Journal: Arch Intern Med Date: 2003-07-28
Authors: Darlene H Moak; Raymond F Anton; Patricia K Latham; Konstantin E Voronin; Randolph L Waid; Ramon Durazo-Arvizu Journal: J Clin Psychopharmacol Date: 2003-12 Impact factor: 3.153
Authors: Rachel D Thompson; Jaimee L Heffner; Judith A Strong; Thomas J Blom; Robert M Anthenelli Journal: Alcohol Date: 2010-07-03 Impact factor: 2.405
Authors: Jaimee L Heffner; Jennifer B McClure; Kristin E Mull; Robert M Anthenelli; Jonathan B Bricker Journal: Bipolar Disord Date: 2015-04-25 Impact factor: 6.744